title: Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors.
abstract: OBJECTIVE
  Variability in the frequency of KIT mutations in gastrointestinal mesenchymal tumors has been reported in the literature, and their prognostic value remains uncertain. This retrospective multicenter study included 276 patients with gastrointestinal mesenchymal tumors.
  
  
  METHODS
  We detected c-kit and CD34 protein expression by immunohistochemistry. Mutations in exons 11 and 9 of KIT and exons 12 and 18 of PDGFR were detected by length analysis of polymerase chain reaction products and direct DNA sequencing.
  
  
  RESULTS
  Eighty-seven percent of the tumors analyzed were c-kit positive, with gastric tumors expressing CD34 more frequently than other tumors (86% vs. 52%; P < 0.001). KIT exon 11 mutations were detected in 90 of 179 (50.3%) of c-kit-positive and 12% of c-kit-negative tumors. These mutations showed variation in their length and location. Mutations were heterozygous in 94% of cases. Mutations were more frequent in CD34( +) tumors than in CD34( -) tumors ( P < 0.01), and 9% of tumors had a second mutation in exon 11. Mutations in exon 9 of KIT were present in 5.1% of the gastrointestinal stromal tumors, and mutations of the PDGFR were present in 11% of the KIT -nonmutated tumors. Patient's age, the primary location, size, necrosis, and mitotic counts of tumors were associated with metastases in c-kit-positive tumors. However, mitotic activity was the only independent factor identified in multivariate analysis ( P < 0.001). KIT mutations were slightly more frequent in metastatic than in nonmetastatic tumors (61% vs. 46%; P = 0.06). Deletions of codons 562-579 were more strongly associated with metastases than were deletions of codons 550-561 ( P = 0.0001).
  
  
  CONCLUSIONS
  Mutations in KIT or PDGFR were detected in 58.4% of the c-kit-positive and also in some c-kit-negative tumors.
authors.affiliation: Pathology Department, Ambroise Paré Hospital, Boulogne, France. francois.emile@apr.ap-hop-paris.fr
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Emile
authors.forename: Nathalie
authors.initials: N
authors.lastname: Théou
authors.forename: Séverine
authors.initials: S
authors.lastname: Tabone
authors.forename: Annie
authors.initials: A
authors.lastname: Cortez
authors.forename: Philippe
authors.initials: P
authors.lastname: Terrier
authors.forename: Marie-Thérèse
authors.initials: MT
authors.lastname: Chaumette
authors.forename: Catherine
authors.initials: C
authors.lastname: Julié
authors.forename: Philippe
authors.initials: P
authors.lastname: Bertheau
authors.forename: Anne
authors.initials: A
authors.lastname: Lavergne-Slove
authors.forename: Jean
authors.initials: J
authors.lastname: Donadieu
authors.forename: Alain
authors.initials: A
authors.lastname: Barrier
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
authors.forename: Brigitte
authors.initials: B
authors.lastname: Debuire
authors.forename: Antoinette
authors.initials: A
authors.lastname: Lemoine
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000032:analysis; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008637:Mesenchymoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D008875:Middle Aged; D009154:Mutation; D010641:Phenotype; D016133:Polymerase Chain Reaction / Q000379:methods; D011336:Probability; D011379:Prognosis; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016019:Survival Analysis
chemical_list: D004273:DNA, Neoplasm; D019009:Proto-Oncogene Proteins c-kit